Researchers studied whether two new peanut allergy treatments for children are worth their cost compared to doing nothing. They followed 201 kids aged 1-10 for 10 years and found that both treatments helped kids become less allergic to peanuts and improved their quality of life. One treatment (called PPOIT) worked slightly better for quality of life, while the other (OIT) was a bit cheaper. Both treatments cost more money upfront but provided real benefits that doctors say make them a good value for families dealing with serious peanut allergies.
The Quick Take
- What they studied: Whether two new peanut allergy treatments for kids are worth the money they cost, compared to not treating the allergy at all.
- Who participated: 201 children between ages 1 and 10 years old (average age 5.9 years, about 64% boys) from multiple hospitals in Australia. They were randomly divided into three groups: one getting PPOIT (a treatment with probiotics and peanuts), one getting OIT (peanut treatment alone), and one getting no treatment.
- Key finding: Both treatments helped kids become less allergic to peanuts and feel better overall. PPOIT improved quality of life slightly more, while OIT was a bit cheaper. Compared to no treatment, both cost more money but doctors say the health improvements make them worth the cost.
- What it means for you: If your child has a serious peanut allergy, these treatments may help them become less allergic over time and improve their daily life. However, they cost several thousand dollars and require ongoing medical care. Talk to your allergist about whether one of these treatments is right for your family’s situation and budget.
The Research Details
This was a carefully designed study where researchers randomly assigned children to three groups: one receiving PPOIT (a probiotic combined with peanut powder), one receiving OIT (peanut powder alone), and one receiving no treatment. The children were followed for 10 years total—1.5 years of active treatment, 2 years of follow-up after treatment ended, and 6.5 years of predictions based on the data collected.
Researchers measured two main things: how many kids became less allergic to peanuts (called remission) and how much their quality of life improved. They also tracked all the costs, including treatment costs and costs from any side effects like allergic reactions. The study was conducted in Australia between 2016 and 2019, with final analysis completed in 2025.
This type of study is important because it answers a real-world question that families and doctors care about: Is it worth spending money on these treatments? Just knowing a treatment works isn’t enough—we also need to know if the benefits are worth the cost, especially for families with limited budgets. By comparing the treatments to doing nothing, researchers could show the actual value these treatments provide.
This study is reliable because it was a randomized controlled trial, which is considered the gold standard in medical research. Children were randomly assigned to groups, which helps ensure fair comparison. The study was conducted at multiple hospitals, making results more trustworthy. However, the study was done in Australia, so costs may differ in other countries. The study also included a 6.5-year prediction period based on earlier data, which is less certain than actual measurements.
What the Results Show
Over the 10-year study period, PPOIT cost about A$3,956 per child (Australian dollars), while OIT cost about A$3,582, and no treatment cost only A$249. The main difference in cost came from the treatment itself, while side effects added a few hundred dollars to each treatment group.
For remission (becoming less allergic), PPOIT achieved 34.1% remission per year on average, OIT achieved 35.1%, and no treatment achieved only 7.3%. This means both treatments roughly doubled the chances of kids becoming less allergic compared to doing nothing.
When measuring quality of life improvements (using a standard health measurement called QALYs), PPOIT provided better overall improvements than OIT. Compared to no treatment, PPOIT cost about A$38,435 per year of quality-of-life improvement gained, while OIT cost about A$60,840. For achieving remission specifically, OIT was slightly cheaper at A$1,199 per year of remission, compared to PPOIT at A$1,384.
Both treatments had minor side effects, mostly mild allergic reactions during treatment, but nothing that made the treatments unsafe overall.
The study found that the most important factors affecting whether these treatments were worth the cost were: (1) the price of the treatment product itself, and (2) how much the treatment improved the child’s quality of life. When researchers tested different price scenarios, they found that if treatment costs came down, the treatments would be even better value. The study also showed that improvements in quality of life—like being able to eat at restaurants without fear or attend birthday parties more comfortably—were just as important as becoming less allergic.
This is one of the first studies to look at whether these newer peanut allergy treatments are worth their cost. Previous studies had shown these treatments work to reduce allergies, but this research adds important information about real-world value. The findings support what doctors have been hoping: that these treatments provide enough benefit to justify their cost for families dealing with serious peanut allergies.
The study followed children for only 10 years, and some of that time (6.5 years) was based on predictions rather than actual data, which is less certain. The study was done in Australia, so costs and healthcare systems may be different in other countries. The study included only 201 children, which is a moderate size—larger studies might show slightly different results. The study didn’t look at what happens if kids stop being allergic completely or if the benefits last beyond 10 years. Finally, the study didn’t include children with very severe allergies or other medical conditions, so results may not apply to all children with peanut allergies.
The Bottom Line
For children with confirmed peanut allergies, both PPOIT and OIT appear to be good value compared to no treatment, with moderate confidence. PPOIT may be slightly better if quality of life is the main concern. OIT may be slightly better if cost is the main concern. These treatments should only be considered under close medical supervision by an allergist. The decision to pursue treatment should be made together with your child’s doctor, considering your family’s budget, your child’s allergy severity, and how much the allergy affects daily life.
These findings are most relevant for families with children who have confirmed peanut allergies and experience significant impact on their daily lives. Children ages 1-10 are the focus of this research. These treatments may be especially valuable for families where the allergy causes anxiety, limits social activities, or creates safety concerns. Families with very limited budgets may need to discuss payment options with their doctor. These findings are less relevant for children with mild allergies that don’t significantly affect daily life, or for families who prefer to manage allergies through strict avoidance.
Active treatment lasts about 1.5 years, during which children gradually eat increasing amounts of peanut powder. Most improvements in remission and quality of life appear within the first 2 years. However, the full benefits may take several years to fully develop, and the study tracked benefits for up to 10 years. Families should expect this to be a long-term commitment, not a quick fix.
Want to Apply This Research?
- Track weekly peanut exposure amounts (in grams) and any allergic reactions experienced, along with a quality-of-life score (1-10 scale) measuring comfort in social eating situations, anxiety about peanut exposure, and daily activity limitations.
- If pursuing treatment, use the app to log daily peanut doses, set reminders for appointments, track side effects, and monitor gradual increases in peanut tolerance. For families not pursuing treatment, track accidental exposures and allergic reactions to document the impact of the allergy on daily life.
- Establish a baseline quality-of-life score before treatment starts. Monthly, review trends in remission progress (ability to tolerate larger amounts), side effect frequency, and quality-of-life improvements. Share this data with your allergist at regular appointments to assess whether treatment is providing expected benefits and to make adjustments if needed.
This research summary is for educational purposes only and should not replace professional medical advice. Peanut allergy treatments like OIT and PPOIT carry risks including allergic reactions and should only be pursued under direct supervision of a qualified allergist. The decision to pursue treatment should be made in consultation with your child’s healthcare provider, considering your child’s specific allergy severity, medical history, and individual circumstances. This study was conducted in Australia and costs, availability, and healthcare systems may differ in your location. Always consult with your allergist before starting any new allergy treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.